NOMURA HOLDINGS INC-SPON ADR (NMR) Fundamental Analysis & Valuation

NYSE:NMR • US65535H2085

Current stock price

7.54 USD
+0.14 (+1.89%)
At close:
7.5841 USD
+0.04 (+0.58%)
After Hours:

This NMR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. NMR Profitability Analysis

1.1 Basic Checks

  • NMR had positive earnings in the past year.
  • In the past year NMR had a positive cash flow from operations.
  • In the past 5 years NMR has always been profitable.
  • The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

  • The Return On Assets of NMR (0.61%) is worse than 68.59% of its industry peers.
  • The Return On Equity of NMR (10.62%) is better than 63.22% of its industry peers.
  • NMR's Return On Invested Capital of 0.68% is on the low side compared to the rest of the industry. NMR is outperformed by 67.77% of its industry peers.
  • NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.16%.
  • The 3 year average ROIC (0.42%) for NMR is below the current ROIC(0.68%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROIC 0.68%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • With a Profit Margin value of 8.05%, NMR is not doing good in the industry: 60.33% of the companies in the same industry are doing better.
  • In the last couple of years the Profit Margin of NMR has declined.
  • NMR has a worse Operating Margin (11.60%) than 64.88% of its industry peers.
  • In the last couple of years the Operating Margin of NMR has declined.
  • With a Gross Margin value of 43.38%, NMR perfoms like the industry average, outperforming 46.28% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NMR has declined.
Industry RankSector Rank
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. NMR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NMR has less shares outstanding
  • Compared to 5 years ago, NMR has less shares outstanding
  • Compared to 1 year ago, NMR has an improved debt to assets ratio.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

  • NMR has an Altman-Z score of -0.23. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
  • NMR has a worse Altman-Z score (-0.23) than 80.99% of its industry peers.
  • NMR has a Debt/Equity ratio of 10.65. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 10.65, NMR is doing worse than 88.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Altman-Z -0.23
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

  • NMR has a Current Ratio of 0.27. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.27, NMR is doing worse than 84.30% of the companies in the same industry.
  • A Quick Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.27, NMR is doing worse than 84.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NMR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.84% over the past year.
  • NMR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.96% yearly.
  • NMR shows a decrease in Revenue. In the last year, the revenue decreased by -4.21%.
  • The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%

3.2 Future

  • Based on estimates for the next years, NMR will show a small growth in Earnings Per Share. The EPS will grow by 4.80% on average per year.
  • NMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.78% yearly.
EPS Next Y13.1%
EPS Next 2Y4.27%
EPS Next 3Y4.8%
EPS Next 5YN/A
Revenue Next Year-16.36%
Revenue Next 2Y-7.78%
Revenue Next 3Y-4.78%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100

More info and screens

Find the best growth stocksShow best growing peers

5

4. NMR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.54, which indicates a very decent valuation of NMR.
  • Compared to the rest of the industry, the Price/Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 66.94% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, NMR is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.35, which indicates a very decent valuation of NMR.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 70.66% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.83. NMR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.54
Fwd PE 9.35
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 68.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.18
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • NMR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.73
PEG (5Y)0.87
EPS Next 2Y4.27%
EPS Next 3Y4.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. NMR Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.22%, NMR is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 6.94, NMR has a dividend in line with its industry peers.
  • NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
Industry RankSector Rank
Dividend Yield 4.22%

5.2 History

  • On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
  • NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
  • NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

5.3 Sustainability

  • NMR pays out 45.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of NMR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP45.53%
EPS Next 2Y4.27%
EPS Next 3Y4.8%
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NMR Fundamentals: All Metrics, Ratios and Statistics

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (3/16/2026, 5:48:37 PM)

After market: 7.5841 +0.04 (+0.58%)

7.54

+0.14 (+1.89%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-30
Earnings (Next)05-10
Inst Owners42.89%
Inst Owner Change9.13%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.12B
Revenue(TTM)4.63T
Net Income(TTM)370.05B
Analysts72.31
Price Target8.52 (13%)
Short Float %0.1%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield 4.22%
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP45.53%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.44%
PT rev (3m)10.7%
EPS NQ rev (1m)-7.95%
EPS NQ rev (3m)29.28%
EPS NY rev (1m)2.31%
EPS NY rev (3m)4.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)2.22%
Revenue NY rev (3m)2.22%
Valuation
Industry RankSector Rank
PE 9.54
Fwd PE 9.35
P/S 0.77
P/FCF N/A
P/OCF 5.57
P/B 1.01
P/tB 1.03
EV/EBITDA 20.18
EPS(TTM)0.79
EY10.48%
EPS(NY)0.81
Fwd EY10.69%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)1.35
OCFY17.97%
SpS9.83
BVpS7.46
TBVpS7.29
PEG (NY)0.73
PEG (5Y)0.87
Graham Number11.51
Profitability
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROCE 1.68%
ROIC 0.68%
ROICexc 0.76%
ROICexgc 0.77%
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Debt/EBITDA 62.4
Cap/Depr 1450.41%
Cap/Sales 19.46%
Interest Coverage 0.21
Cash Conversion 106.5%
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.23
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
EPS Next Y13.1%
EPS Next 2Y4.27%
EPS Next 3Y4.8%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%
Revenue Next Year-16.36%
Revenue Next 2Y-7.78%
Revenue Next 3Y-4.78%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year27356.2%
EBIT Next 3Y536.99%
EBIT Next 5YN/A
FCF growth 1Y58.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.88%
OCF growth 3YN/A
OCF growth 5YN/A

NOMURA HOLDINGS INC-SPON ADR / NMR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to NMR.


What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.


Can you provide the profitability details for NOMURA HOLDINGS INC-SPON ADR?

NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.


What is the financial health of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.


What is the earnings growth outlook for NOMURA HOLDINGS INC-SPON ADR?

The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 13.1% in the next year.